This HTML5 document contains 24 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00089/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00089/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00089/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00089/identifier/wikipedia/

Statements

Subject Item
n2:DB00089
rdf:type
n3:Drug
n3:description
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.
n3:generalReferences
# http://www.google.com/patents/WO2013006706A1?cl=en # http://www.lens.org/lens/patent/US_4671958_A # http://www.google.ca/patents/US4741900 # http://www.google.com/patents/US5162504
n3:group
approved
n3:indication
For diagnosis of prostate cancer and detection of intra-pelvic metastases.
owl:sameAs
n8:DB00089 n14:DB00089
dcterms:title
Capromab
adms:identifier
n6:57902-817-01 n9:DB00089 n10:Capromab n13:PA164745489
n3:mechanismOfAction
Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
n3:packager
n15:271B4432-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
n3:synonym
Capromab pendetide In 111 Capromab pendetide
n3:volumeOfDistribution
* 4 ± 2.1 L
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
145464-28-4
n3:category
n3:clearance
* 42 +/- 22 mL/hr
n3:containedIn
n11:271B4433-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n12:271B4434-363D-11E5-9242-09173F13E4C5